Clinical Trials
509
Trial Phases
6 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (313 trials with phase data)• Click on a phase to view related trials
REST4-AAA Registry
- Conditions
- Abdominal Aortic Aneurysm
- First Posted Date
- 2025-07-09
- Last Posted Date
- 2025-07-09
- Lead Sponsor
- RenJi Hospital
- Target Recruit Count
- 70
- Registration Number
- NCT07056491
- Locations
- 🇨🇳
Ren Ji Hospital Afflited to School of Medicine, Shanghai Jiao Tong University, Shanghai, Shanghai, China
The Effectiveness of a TTM-based Multidisciplinary Collaboration on Cardiac Rehabilitation Outcomes in Patients With AMI
- Conditions
- Acute Myocardial Infarction
- First Posted Date
- 2025-07-01
- Last Posted Date
- 2025-07-01
- Lead Sponsor
- RenJi Hospital
- Target Recruit Count
- 86
- Registration Number
- NCT07045220
- Locations
- 🇨🇳
Renji Hospital, Shanghai, China
🇨🇳Renji Hospital, Shanghai, China
HAIC + Atezolizumab Plus Bevacizumab in Unresectable HCC
- Conditions
- Unresectable Hepatocellular Carcinoma
- First Posted Date
- 2025-07-01
- Last Posted Date
- 2025-07-01
- Lead Sponsor
- RenJi Hospital
- Target Recruit Count
- 28
- Registration Number
- NCT07045558
- Locations
- 🇨🇳
Renji Hospital affiliated to Shanghai Jiao Tong University, School of Medicine, Shanghai, China
AAA-CTA Cohort Registry
- Conditions
- Abdominal Aortic AneurysmImage
- First Posted Date
- 2025-06-26
- Last Posted Date
- 2025-06-26
- Lead Sponsor
- RenJi Hospital
- Target Recruit Count
- 1000
- Registration Number
- NCT07039825
- Locations
- 🇨🇳
Ren Ji Hospital Afflited to School of Medicine, Shanghai Jiao Tong University, Shanghai, China
Efficacy of Semaglutide in Improving Neurological Outcomes After Endovascular Thrombectomy for Acute Ischemic Stroke: A Randomized Double-Blind Controlled Trial
- Conditions
- Acute Ischemic Stroke
- Interventions
- Drug: Normal Saline
- First Posted Date
- 2025-06-22
- Last Posted Date
- 2025-06-22
- Lead Sponsor
- RenJi Hospital
- Target Recruit Count
- 436
- Registration Number
- NCT07030621
- Locations
- 🇨🇳
Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China
- Prev
- 1
- 2
- 3
- 4
- 5
- 102
- Next
News
Lenvatinib-Tislelizumab Combo Shows Promising 93% Response Rate in Rare Hereditary Kidney Cancer
Phase 2 study demonstrates remarkable 93.3% objective response rate for lenvatinib plus tislelizumab in treating fumarate hydratase-deficient renal cell carcinoma, with 20% achieving complete response.